- 丙酮酸激酶缺乏症
- 珠蛋白生成障碍性贫血
- 红细胞膜缺陷症 - 检验
- 血液病的预防
- 为什么会得白血病?
- 白血病是遗传病吗
- 输血会传染上白血病吗?
- 白血病会传染吗?
- MDS维也纳诊断标准,MDS的...
- 铁负荷过多
- 铁负荷过多-诊断标准
- 去铁
- 分子靶向治疗??肿瘤治疗新手段
- 侵袭性真菌病
- 欧洲血液病学会
- 急性早幼粒细胞白血病诊疗新进展
- Coombs试验
- A Phase II Rand...
- Effectiveness o...
- Anti-tumour eff...
- Wilms' tumo...
- Hematopoietic c...
- Differentiation...
- Clonality inves...
- A delayed yet d...
- Effect of low-d...
- Appropriate tim...
- 原发性血小板减少性紫癜的治疗进...
- 问:什么是靶向治疗,它有什么好...
- 万珂治疗多发性骨髓瘤不良反应护...
- 万珂治疗骨髓瘤
- 骨髓衰竭:儿童和成人要分别对待
- 坏死性淋巴结炎
- MDS的WHO分型预后积分系统...
- MDS的国际预后积分系统(IP...
- ICUS诊断要点
- MDS病理活检的意义
- 维也纳标准
- 2008年MDS的WHO分型
- MDS诊断及分型标准
- 慢性淋巴细胞性白血病
- 珠蛋白生成障碍性贫血
- 美罗华治疗血小板减少的观察与护...
- 骨髓增生异常综合症诊断与分型的...
- Decitabine (商品名...
- 骨髓增生异常综合征(MDS):
- 染色体检测在骨髓增生异常综合征...
- 现代化生活与血液病
- 骨髓增生异常综合征的诊断和治疗...
- 不做下一个
- 2001年WHO淋巴瘤分类特点
- 2001年WHO淋巴瘤分类
- Intracellular c...
- 血友病甲
- Ann Arbor stagi...
- LYMPHOMA
- 慢性髓细胞白血病
- 转帖
- Imatinib、Mechanism of action
- 作者:常春康|发布时间:2009-03-09|浏览量:1052次
Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. It occupies the TK active site, leading to a decrease in activity.
There are a large number of TK enzymes in the body, including the insulin receptor. Imatinib is specific for the TK domain in abl (the Abelson proto-oncogene), c-kit and PDGF-R (platelet-derived growth factor receptor).上海市第六人民医院血液内科常春康
In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of abl with bcr (breakpoint cluster region), termed bcr-abl. As this is now a continuously active tyrosine kinase, imatinib is used to decrease bcr-abl activity.
The active sites of tyrosine kinases each have a binding site for ATP. The enzymatic activity catalyzed by a tyrosine kinase is the transfer of the terminal phosphate from ATP to tyrosine residues on its substrates, a process known as protein tyrosine phosphorylation. Imatinib works by binding to the ATP binding site of bcr-abl and inhibiting the enzyme activity of the protein competitively.
Imatinib is quite selective for bcr-abl ? it does also inhibit other targets mentioned above (c-kit and PDGF-R), but no other known tyrosine kinases. Imatinib also inhibits the abl protein of non-cancer cells but cells normally have additional redundant tyrosine kinases which allow them to continue to function even if abl tyrosine kinase is inhibited. Some tumor cells, however, have a dependence on bcr-abl.[5] Inhibition of the bcr-abl tyrosine kinase also stimulates its entry in to the nucleus, where it is unable to perform any of its normal anti-apoptopic functions.[7]
TA的其他文章: